title: Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials.
abstract: OBJECTIVE
  To address the safety and efficacy of drug-eluting stents (DES) in the treatment of intermediate lesions, we performed a pooled analysis of four randomized DES versus bare-metal stent (BMS) trials and assessed outcomes among patients with intermediate lesions.
  
  
  BACKGROUND
  Before the introduction of DES, intermediate coronary lesions were commonly managed based on physiologic or anatomic assessment of lesion severity. The DES may challenge this paradigm.
  
  
  METHODS
  The study population involved 167 of 2,478 randomized patients (6.7%) with intermediate lesions (diameter stenosis <50% [mean 44%] by quantitative coronary angiography) from the Sirolimus-coated Bx Velocity Balloon Expandable Stent in the Treatment of Patients with De Novo Coronary Artery Lesions (SIRIUS), TAXUS-IV, and the First and Second First Use to Underscore Restenosis Reduction with Everolimus (FUTURE-I and -II) trials. End points examined included early (in-hospital and 30-day) and late (1-year) major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis, and follow-up angiographic restenosis.
  
  
  RESULTS
  Patients with intermediate lesions randomized to DES versus BMS had low rates of 30-day MACE (1.1% vs. 4.0% respectively; p = 0.22). At one-year follow-up, patients treated with DES versus BMS had similar rates of cardiac death (0% vs. 2.7%, respectively; p = 0.11) and MI (3.4% vs. 5.4%; p = 0.49) but markedly lower rates of TVR (3.4% vs. 20.3%; p = 0.0004), MACE (5.6% vs. 25.4%; p = 0.0003), and binary angiographic restenosis (1.8% vs. 34.0%; p < 0.0001). No patient in either group developed stent thrombosis.
  
  
  CONCLUSIONS
  Compared with BMS, treatment of intermediate lesions with DES appears safe and results in a marked reduction in clinical and angiographic restenosis. The efficacy of DES may require a reevaluation of current treatment paradigms for intermediate lesions.
authors.affiliation: Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10032, USA. jm2456@columbia.edu
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Moses
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
authors.forename: Eugenia
authors.initials: E
authors.lastname: Nikolsky
authors.forename: Gary S
authors.initials: GS
authors.lastname: Mintz
authors.forename: George
authors.initials: G
authors.lastname: Dangas
authors.forename: Eberhard
authors.initials: E
authors.lastname: Grube
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Ellis
authors.forename: Alexandra J
authors.initials: AJ
authors.lastname: Lansky
authors.forename: Giora
authors.initials: G
authors.lastname: Weisz
authors.forename: Martin
authors.initials: M
authors.lastname: Fahy
authors.forename: Yingbo
authors.initials: Y
authors.lastname: Na
authors.forename: Mary E
authors.initials: ME
authors.lastname: Russell
authors.forename: Dennis
authors.initials: D
authors.lastname: Donohoe
authors.forename: Martin B
authors.initials: MB
authors.lastname: Leon
authors.forename: Roxana
authors.initials: R
authors.lastname: Mehran
mesh_terms: D023903:Coronary Restenosis / Q000628:therapy*; D004867:Equipment Design; D006331:Heart Diseases / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008670:Metals; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D015607:Stents / Q000009:adverse effects
chemical_list: D008670:Metals; D004364:Pharmaceutical Preparations